LifeMD, Inc. (NASDAQ:LFMD) Given Average Rating of “Moderate Buy” by Brokerages

Posted by Brian Himes on Jun 30th, 2026

LifeMD, Inc. (NASDAQ:LFMD – Get Free Report) has received an average recommendation of “Moderate Buy” from the ten ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $9.1429.

Several brokerages recently commented on LFMD. BTIG Research reiterated a “buy” rating and set a $10.00 price target on shares of LifeMD in a research report on Monday, May 4th. Mizuho raised shares of LifeMD from a “neutral” rating to an “outperform” rating and lifted their target price for the stock from $6.00 to $8.00 in a research note on Monday, March 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of LifeMD in a research note on Tuesday, March 10th. Loop Capital set a $10.00 target price on shares of LifeMD in a research note on Thursday, March 12th. Finally, Wall Street Zen upgraded LifeMD from a “sell” rating to a “hold” rating in a report on Saturday, June 20th.

Read Our Latest Analysis on LifeMD

LifeMD Trading Up 1.7%

LFMD opened at $4.20 on Thursday. The firm has a market capitalization of $203.12 million, a PE ratio of 84.02 and a beta of 1.98. LifeMD has a 12-month low of $2.56 and a 12-month high of $14.43. The firm has a 50 day moving average of $4.57 and a two-hundred day moving average of $3.86.

LifeMD (NASDAQ:LFMD – Get Free Report) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.06). The firm had revenue of $50.16 million for the quarter, compared to analyst estimates of $48.84 million. LifeMD had a negative return on equity of 150.88% and a net margin of 2.37%. As a group, analysts predict that LifeMD will post -0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On LifeMD

Large investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of LifeMD by 4.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,647 shares of the company’s stock worth $270,000 after purchasing an additional 2,235 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of LifeMD by 110.4% during the second quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after acquiring an additional 2,452 shares during the last quarter. SG Americas Securities LLC grew its position in shares of LifeMD by 13.8% during the fourth quarter. SG Americas Securities LLC now owns 25,298 shares of the company’s stock worth $86,000 after acquiring an additional 3,061 shares during the last quarter. Invesco Ltd. grew its position in shares of LifeMD by 18.8% during the fourth quarter. Invesco Ltd. now owns 24,464 shares of the company’s stock worth $83,000 after acquiring an additional 3,870 shares during the last quarter. Finally, Rhumbline Advisers grew its position in shares of LifeMD by 8.7% during the second quarter. Rhumbline Advisers now owns 53,589 shares of the company’s stock worth $730,000 after acquiring an additional 4,281 shares during the last quarter. Institutional investors and hedge funds own 35.52% of the company’s stock.

LifeMD Company Profile

(Get Free Report)

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.